IGF-1 DES

1. Introduction to Insulin-Like Growth Factor-1 DES (IGF-1 DES)

The peptide Insulin-Like Growth Factor-1 DES (IGF-1 DES) is a truncated variant of the naturally occurring Insulin-Like Growth Factor-1 (IGF-1) protein. This research-grade peptide is specifically utilized in neuroscience and developmental biology studies due to its potent influence on cell growth, survival, and, crucially, synaptic health and plasticity.

IGF-1 DES lacks the N-terminal tripeptide (Gly-Pro-Glu) of the full-length IGF-1 molecule, resulting in a compound with a shorter half-life and unique binding characteristics. The structural modification is believed to confer enhanced biological activity in certain contexts, particularly those requiring efficient central nervous system (CNS) engagement.

2. Research Context: The Role of IGF-1 DES in Neuro-Development

IGF-1 DES is a primary tool for researching neurodevelopmental disorders due to its ability to influence synaptic health. Its mechanism of action involves binding to the IGF-1 receptor (IGF-1R), a receptor tyrosine kinase that initiates intracellular signaling cascades critical for neuronal development and function.

The table below summarizes key research findings that support the use of IGF-1 DES in neuro-developmental research:

Research Area

Key Finding/Mechanism

Research Model

Autism Models

IGF-1 variants can reverse behavioral deficits, including repetitive behaviors and social impairments.

Mice

Synaptic Transmission

Research indicates a ~40% enhancement in excitatory synaptic transmission in hippocampal neurons treated with IGF-1 DES.

In vitro (Hippocampal Neurons)

Brain Penetration

The truncated structure allows for more efficient crossing of the blood-brain barrier (BBB) compared to full-length IGF-1.

Animal Models

Neuronal Survival

Supports neurogenesis and provides neuroprotection against various stressors.

Various

3. Applications in Neuroscience Assays and Disease Models

Autism Spectrum Disorder (ASD) Models

Research into Autism Spectrum Disorder (ASD) often focuses on restoring synaptic function and mitigating behavioral symptoms. Studies in mice suggest that IGF-1 variants, including the DES variant, can reverse behavioral deficits associated with ASD-like phenotypes.

The primary research goal is to understand how modulating the IGF-1 pathway can normalize impaired neural circuit function that underlies core ASD symptoms such as:

• Repetitive behaviors
• Social impairments
• Communication deficits

Synaptic Plasticity Studies

Synaptic plasticity, the ability of synapses to strengthen or weaken over time, is the fundamental mechanism for learning and memory. IGF-1 DES is a valuable reagent for studying this process.

Research has shown a notable enhancement in excitatory synaptic transmission:

• Observation: ~40% enhancement in excitatory synaptic transmission.
• Location: Observed in hippocampal neurons.
• Significance: The hippocampus is a critical region for memory formation, making IGF-1 DES a powerful tool for investigating the molecular basis of learning and memory enhancement or impairment.

4. Pharmacokinetic and Structural Advantages

Efficient Blood-Brain Barrier (BBB) Penetration

One significant advantage of IGF-1 DES over its full-length counterpart is its structural modification, which influences its ability to enter the central nervous system (CNS).

The truncated structure allows for more efficient crossing of the blood-brain barrier compared to full-length IGF-1 in animal models. This superior brain penetration makes IGF-1 DES an essential reagent for studies that require reliable CNS action without the complications of systemic delivery limitations.

Receptor Binding Profile

IGF-1 DES retains high affinity for the IGF-1R but exhibits a lower affinity for the circulating IGF-binding proteins (IGFBPs). This decreased binding to IGFBPs is hypothesized to contribute to its increased biological potency in vivo by making more of the peptide available to bind to its target receptor (IGF-1R) at the cellular level.

5. Ideal Applications Summary

IGF-1 DES is Ideal For researchers working on the following experimental assays:

• Neuroscience Assays: Studying neuronal growth, differentiation, and survival in cell cultures or animal models.
• Autism Spectrum Disorder (ASD) Models: Investigating therapeutic avenues and underlying pathology in relevant in vivo models.
• Synaptic Plasticity Studies: Exploring the mechanisms of long-term potentiation (LTP) and long-term depression (LTD) in structures like the hippocampus.

6. Regulatory Status

Status: Experimental Reagent.

IGF-1 DES is intended strictly for in vitro or in vivo laboratory research and development purposes only. It is not approved for human or animal use outside of the research context. All handling and use must adhere to relevant institutional and governmental guidelines for experimental biological reagents.

For detailed protocols and safety data, please refer to the Material Safety Data Sheet (MSDS) and the Certificate of Analysis (CoA), which can be found in the attached documentation File.

7. Storage and Handling Recommendations

Parameter

Recommendation

Storage Temperature (Short-Term)

-20°C (Frozen)

Storage Temperature (Long-Term)

-80°C (Ultra-Frozen)

Solvent for Reconstitution

Sterile, low-pH solution (e.g., 0.1% Acetic Acid)

Working Concentration

Varies by assay; typically picomolar (pM) to nanomolar (nM) range

Stability

Minimize freeze-thaw cycles. Aliquot stock solutions for single use.

8. Further Research and Future Directions

The investigation of IGF-1 DES continues to be a vibrant area of research, particularly in the intersection of developmental disorders and growth factor signaling. Future studies may focus on:

1. Specific Receptor Subtypes: Detailed analysis of IGF-1 DES's interaction with various IGF-1R signaling complexes.
2. Dosimetry and Efficacy: Establishing optimal dosing regimens for in vivo models of various neurodevelopmental disorders.
3. Combination Therapies: Researching the synergistic effects of IGF-1 DES when administered alongside other neuroactive compounds.

Interested researchers are invited to attend the upcoming seminar on 'Peptide Therapeutics in Neurodevelopment' at the Place on Date. More details are available via this calendar event link Calendar event.

--- End of Document ---